Completed PHASE1 INTERVENTIONAL 4-arm NCT02003547

A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects

A Single Centre, Placebo-Controlled, Double-Masked, Sequential Designed Study to Evaluate 3 Ophthalmic Formulations of AMA0076 in Healthy Subjects

Sponsor: Amakem, NV

Conditions Eye Disease Glaucoma Ocular Hypertension

Interventions AMA0076 Placebo

Updated 5 times since 2017 Last updated: May 1, 2014 Started: Sep 30, 2013 Primary completion: Dec 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Eye Disease and Glaucoma and is currently completed. Amakem, NV leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amakem, NV

Data source: Amakem, NV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ruddington, United Kingdom